CYBIN INC.

Helus Pharma announced that CEO Michael Halstead will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference on August 12, 2026. The clinical-stage pharmaceutical company is focused on developing novel serotonergic agonists (NSAs) for mental health conditions. Its pipeline includes HLP003 in Phase 3 for major depressive disorder with Breakthrough Therapy Designation, and HLP004 in Phase 2 for generalized anxiety disorder.

Helus Pharma, the commercial operating name of Cybin Inc., announced the immediate appointment of Michael Halstead as its new Chief Executive Officer. Halstead brings 25 years of industry experience, including his role as President of Intra-Cellular Therapies, where he oversaw the company's growth and its $14.6 billion acquisition by Johnson & Johnson. His appointment comes as Helus Pharma advances its lead drug HLP003 through late-stage clinical development, with topline Phase 3 data expected in Q4 2026, and prepares for potential commercialization.

Helus Pharma announced the appointment of Michael Halstead as its new Chief Executive Officer, effective immediately. Mr. Halstead brings 25 years of industry experience, including his recent role as President of Intra-Cellular Therapies, Inc., where he was instrumental in the successful development and commercialization of CAPLYTA® and led the company's US$14.6 billion sale to Johnson & Johnson. His appointment comes as Helus Pharma advances HLP003 through late-stage clinical development, with topline data from its pivotal Phase 3 study expected in Q4 2026, and continues development of HLP004.

Helus Pharma announced the completion of enrollment in its APPROACH Phase 3 pivotal study for HLP003, a novel serotonergic agonist for Major Depressive Disorder (MDD). This milestone advances the company toward the expected release of topline data in the fourth quarter of 2026. HLP003 previously received FDA Breakthrough Therapy Designation, and Phase 2 data demonstrated durable efficacy with significant reductions in MADRS scores and high remission rates. Enrollment is also continuing in EMBRACE, the second pivotal study in the PARADIGM Program.

Helus Pharma (Cybin Inc.) announced and subsequently closed an underwritten public offering, raising approximately US$50 million in aggregate gross proceeds. The company issued 10,309,280 common shares at a price of US$4.85 per share. The net proceeds from this offering are intended to advance its HLP003, HLP004, and HLP005 programs, and for general corporate purposes and working capital.

Helus Pharma reported its fiscal year 2026 financial results and significant business highlights, including the successful closing of a $50 million underwritten offering. The company's HLP003 Phase 3 APPROACH study for Major Depressive Disorder has surpassed 88% enrollment and is on track for topline data in Q4 2026. Additionally, positive Phase 2 data for HLP004 in Generalized Anxiety Disorder was reported, and the company strengthened its scientific and medical leadership team. While the company reported a net loss of $148.0 million for fiscal year 2026, it ended the period with $157.3 million in cash.

Helus Pharma reported audited financial results for its fiscal year ended March 31, 2026, with a net loss of $148.0 million, an increase from the prior year, driven by advanced clinical trials. The company recently closed a $50 million underwritten offering, bolstering its balance sheet. Key business highlights include HLP003 Phase 3 APPROACH study surpassing 88% enrollment, with topline data anticipated in Q4 2026, and positive Phase 2 results for HLP004 in Generalized Anxiety Disorder.

Helus Pharma announced the closing of its previously announced underwritten offering, generating aggregate gross proceeds of US$50 million. The company offered 10,309,280 common shares at US$4.85 per share. The net proceeds are intended to advance the company's HLP003, HLP004, and HLP005 programs, as well as for working capital and general corporate purposes.

Helus Pharma, a clinical-stage pharmaceutical company, announced the pricing of an underwritten offering of 10,309,280 common shares at US$4.85 per share, raising aggregate gross proceeds of US$50 million. The company intends to use the net proceeds to advance its HLP003, HLP004, and HLP005 programs, as well as for working capital and general corporate purposes. The offering, managed by Cantor and Barclays, is expected to close on June 25, 2026.

Helus Pharma announced that enrollment in its APPROACH Phase 3 clinical trial for HLP003, an adjunctive treatment for major depressive disorder (MDD), has surpassed 86% and is progressing as planned. The company anticipates a topline data readout in Q4 2026. HLP003, which has received FDA Breakthrough Therapy Designation, previously demonstrated strong long-term efficacy in Phase 2 data, including a ~23-point reduction in MADRS score and improved response and remission rates of 100% and 71% respectively at 12 months.